Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$2.10
-$0.06(-10.00%)
At close: 4:00 PM EST
$2.10
-$0.06(-10.00%)
Day’s Range― - ―
52-Week Range$0.88 - $3.46
Previous CloseN/A
Volume151.09K
Average Volume (3M)95.05K
Market Cap
$31.20M
Enterprise Value$57.74
Total Cash (Recent Filing)$202.51K
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding26,000,443
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Pipeline (CNS & Oncology)A clear, durable strategic focus on CNS disorders and oncology concentrates R&D resources on high unmet-need areas. Clinical-stage assets create discrete milestone-driven value inflection opportunities (data readouts, approvals, partnering) that can materially derisk and transform the company's prospects over months.
Improving Operating Cash Flow / Reduced BurnA marked reduction in operating cash burn is a durable operational improvement: lowering monthly runway consumption improves the chance to reach clinical milestones without immediate dilutive financing. Sustained lower burn enhances strategic optionality for partnerships or targeted financing over the next several months.
Moderate Leverage And Tangible Equity BaseRelative to many early-stage biotechs, moderate leverage and a tangible equity cushion provide some balance-sheet stability. This capital structure lowers immediate solvency risk, giving management a firmer platform to fund near-term clinical programs or negotiate non-dilutive partnerships over the medium term.
Bears Say
Persistent UnprofitabilityConsistent, multi-year net losses materially erode equity and limit internal funding for R&D. Ongoing negative earnings reduce flexibility to self-finance trials and increase dependency on external capital, raising dilution and refinancing risks that can alter strategic plans and hamper long-term value creation.
Weak Cash Generation And Negative Free Cash FlowSustained negative operating and free cash flow forces reliance on new financing or partnerships to sustain operations. This structural cash-generation shortfall increases execution risk for clinical programs, constrains ability to scale or hire, and raises the probability of dilutive financing near-term unless trends continue to improve.
Tiny Revenue Base And High Operating Expense PressureA minimal, volatile revenue base combined with operating expenses that exceed gross profit means the company lacks commercial scale and margin sustainability. Without material, recurring revenues or licensing/partnership inflows, the business model remains dependent on intermittent financing or milestone payments to fund operations.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.88 and its highest was $3.46 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $31.20M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 117 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 26,000,443 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ABVC BioPharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
447.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.65%
Trailing 12-Months
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.39% Mutual Funds
<0.01% Other Institutional Investors
97.17% Public Companies and
Individual Investors